GGrantIndex
Sort

15,273 grants matching antimicrobial resistance

Direct-from-specimen identification of pathogens common in endocarditis

$1,049,999
Alon Singer · Helixbind, Inc. · R44 · FY2025 · AI

Development of a Novel Oral Antibiotic for the Treatment of Drug Resistant Gonorrhea

$1,049,943
Laurene Wang · Aimmax Therapeutics, Inc. · R44 · FY2025 · AI

Exploiting Riboswitch Sensors to Reveal Antibiotics Uptake and Retention in Gram Negative Bacteria

$1,047,570
Ronald R Breaker · Yale University · R01 · FY2022 · AI

Cross-Kingdom Vaccine Targeting Healthcare-Associated Priority Pathogens

$1,047,323
Ashraf S. Ibrahim · Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center · R01 · FY2022 · AI

Sexually Transmitted Infections Clinical Trial Group: Clinical Study of Point-of-Care Diagnostics

$1,046,425
Jeffrey Klausner · Social And Scientific Systems, Inc. · N01 · FY2019 · AI

Host defense-stimulating macrocyclic peptides for treatment of MDR bacterial infections

$1,042,376
Michael E Selsted · University Of Southern California · R01 · FY2017 · AI

Host-bacterial interactions determining the spectrum of Mtb transmission

$1,041,944
Padmini Salgame · Rutgers Biomedical And Health Sciences · R01 · FY2025 · AI

Chemistry Core

$1,040,570
Timothy S Bugni · University Of Wisconsin-Madison · U19 · FY2019 · AI

A randomized, double-blind, multi-center comparative effectiveness study of spironolactone versus doxycycline hyclate for the treatment of acne in women

$1,040,468
David J. Margolis · University Of Pennsylvania · U01 · FY2021 · AR

Boosting Innate Immunity Through HIF to Treat Antibiotic-Resistant Infections

$1,036,121
Victor Nizet · University Of California, San Diego · R01 · FY2011 · AI

Chemistry Core

$1,035,799
Timothy S Bugni · University Of Wisconsin-Madison · U19 · FY2023 · AI

Identifying novel anti-infectives by high through-put screening in whole animals

$1,035,268
Frederick M Ausubel · Massachusetts General Hospital · R01 · FY2012 · AI

Bacterial Functions Involved in Cell Growth Control

$1,034,389
Susan Gottesman · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA

Development of novel proteins synthesis inhibitors for MDR tuberculosis

$1,034,057
Richard Edward Lee · St. Jude Children'S Research Hospital · R01 · FY2010 · AI

Mechanisms of Chromosome Maintenance in Bacteria

$1,032,156
Dhruba K Chattoraj · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA

Diagnostics for Rapid Treatment and Control of Multidrug-Resistance in Healthcare

$1,031,385
Lance Robert Peterson · Endeavor Health Clinical Operations · R56 · FY2010 · AI

A randomized, double-blind, multi-center comparative effectiveness study of spironolactone versus doxycycline hyclate for the treatment of acne in women

$1,029,338
David J. Margolis · University Of Pennsylvania · U01 · FY2022 · AR

Integrated Data and Simulation Environment in Public Health Informatics

$1,028,748
Matthew Samore · University Of Utah · P01 · FY2008 · CD

Exploration, conservation, & development of marine biodiversity in Fiji and the S

$1,028,666
Mark E Hay · Georgia Institute Of Technology · U19 · FY2014 · TW

Novel polymeric materials with improved durability in the oral environment: tailoring responses to host and bacterial enzymes with anti-proteolytic and ecology-based antimicrobial approaches.

$1,028,106
Carmem S. Pfeifer · Oregon Health & Science University · R35 · FY2025 · DE

An automated culture-free system for the identification of bloodstream infections direct from blood

$1,027,841
Alon Singer · Helixbind, Inc. · R44 · FY2025 · AI

Identification of novel MDR antimicrobials from human microbiome symbioses

$1,027,236
Nasia Safdar · University Of Wisconsin-Madison · U19 · FY2021 · AI

Biomimetic Macrophage Membrane-Coated Nanosponges: A Novel Therapeutic for Multidrug-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii Hospital-Associated Pneumonia

$1,027,000
Victor Nizet · University Of California, San Diego · R01 · FY2023 · AI

Protective film-forming disinfectant based on chitosan/water/ethanol tertiary solutions

$1,025,000
David John Meisinger · Vrm Labs Inc · R44 · FY2024 · AI

Protective film-forming disinfectant based on chitosan/water/ethanol tertiary solutions

$1,025,000
David John Meisinger · Vrm Labs Inc · R44 · FY2025 · AI